Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 11/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.42 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279927 | 0.83 | ROCK2 (0.43) | PTK2SYKJAK3BTK | |
| SCHEMBL12085337 | 0.81 | PTK2 (0.50) | PTK2SYKBRAFJAK3BTK | |
| SCHEMBL13406586 | 0.80 | CDK1 (0.43) | CDK1CDK4SYKMEN1NPC1 | |
| SCHEMBL4381772 | 0.79 | PTK2 (0.44) | PTK2JAK3BTK | |
| SCHEMBL14666810 | 0.79 | BRD4 (0.46) | PTK2BRAFJAK3BTK | |
| SCHEMBL3286398 | 0.78 | SYK (0.49) | CDK1PTK2SYKJAK3BTK | |
| SCHEMBL1017841 | 0.78 | BRD4 (0.47) | CDK1PTK2SYKBRAFJAK3 | |
| SCHEMBL13387040 | 0.77 | CDK1 (0.54) | CDK1CDK4SYKMAPK3 | |
| SCHEMBL4380216 | 0.76 | LRRK2 (0.51) | PTK2SYKJAK3BTK | |
| SCHEMBL12085362 | 0.76 | TTBK1 (0.53) | PTK2SYKRAB9AJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2009026107-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | CDK1 278/4885PTK2 196/4885CDK4 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.